Applied Filters
MSD, Pfizer try to stop three Steglatro generics
Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.
Campaigners ask US govt to force down prices for common drugs
Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.
Novo Nordisk and Sandoz settle Victoza patent suit
Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.
Generic Emcure stole COVID-19 vaccine trade secrets, lawsuit claims
US pharma company HDT Bio has accused Emcure Pharmaceuticals of the “blatant theft” of its COVID-19 vaccine technology in a new lawsuit.
Otsuka says Samsca generic infringes
Otsuka Pharmaceuticals has filed a patent infringement suit against MSN Laboratories targeting the company’s planned generic Samsca heart medication.
AbbVie and Alvotech settle all US Humira litigation
AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).
Cipla files defensive patent suit over Ofev generic
Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.
A&O recruits five-strong Goodwin team, launches in Boston
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice.
Otsuka says Teva’s REXULTI generic infringes patents
Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
